ClinicalTrials.gg
Status unknownNCT03225495Updated Jan 17, 2018

Comparison Between Ultra-narrow Diameter Implants (2,75 mm) Without Bone Regeneration Versus Standard Diameter Implants (4,3 mm) in Combination With Bone Regeneration

An interventional study of Standard implant and Ultra-narrow implant in Dental Implant, Narrow Implant and Implant Fracture, sponsored by University of Barcelona. Status unknown at 1 site in Spain. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2018-01-17.

Sponsored by University of Barcelona · Not applicable, Interventional, and Treatment

How we know

The sponsor has not verified this record recently (last verified Jan 2018), so the status shown — last known as Recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
40
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

The main target of the study is to compare ultra-narrow diameter implants (2.75 mm) without bone regeneration versus standard diameter implants (4.3 mm) in combination with bone regeneration. To do so, patients with missing upper central incisors, canines, first or second premolars with alveolar ridges of 6 - 8 mm of thickness will be restored with dental implants. Cone beam computed tomographic examination and clinical values will be registered before and after the surgical procedure at 6 and 12 months.

02

Conditions studied

  • Dental Implant
  • Narrow Implant
  • Implant Fracture
  • Guided Bone Regeneration
03

In context

Lead sponsor

University of Barcelona is the lead sponsor of 100 studies on the registry; 30 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • One missing teeth in position: upper central incisor, canine or premolar
  • alveolar ridge thickness of 6 - 8 mm
  • alveolar ridge height of ≥ 10 mm

Exclusion criteria

Exclusion Criteria:

  • Missing data
  • ASA ≥ III
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
40 participants (estimated)

Study arms

  • Active comparator
    Standard Implant

    Procedure: Standard implant

  • Experimental
    Ultra-narrow Implant

    Procedure: Ultra-narrow implant

Interventions

  • ProcedureStandard implant

    Arm - Standard Implant: implant placement in combination with guided bone regeneration;

  • ProcedureUltra-narrow implant

    Arm - Ultra-narrow implant: implant placement without guided bone regeneration

06

What researchers measure

Primary outcomes

  1. Success

    According to criteria described by Albrektsson et al. 1986

    Time frame: 12 months

07

Study locations

1 of 1 sites recruiting
  • Hospital Odontològic - Universitat de Barcelona
    L'Hospitalet de Llobregat, 08907, Spain
    Recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jul 2017 (actual). Primary completion is estimated for Jul 2018, 12 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 18, 2017
First posted
Jul 21, 2017
StartActual
Jul 1, 2017
Primary completionEst.
Jul 1, 2018
CompletionEst.
Jul 1, 2019
Last update
Jan 17, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 17, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03225495
Collaborators
Adin Implants, Geistlich Pharma AG
Responsible party
Rui Figueiredo (PhD - Assitant Professor, University of Barcelona) — Principal investigator
First posted
Jul 21, 2017
Start date
Jul 1, 2017
Primary completion
Jul 1, 2018 (estimated)
Completion
Jul 1, 2019 (estimated)
Last update
Jan 17, 2018

Study contacts

Rui Figueiredo, PhD
Contact
ruipbfigueiredo@gmail.com
00 34 93 402 42 74

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Jan 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion